{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:15:41Z","timestamp":1794968141245,"version":"4.9.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2834,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1365-2133.2007.08315.x","type":"journal-article","created":{"date-parts":[[2008,2,11]],"date-time":"2008-02-11T04:04:21Z","timestamp":1202702661000},"page":"558-566","source":"Crossref","is-referenced-by-count":602,"title":["Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)"],"prefix":"10.1093","volume":"158","author":[{"given":"J.-H.","family":"Saurat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dubertret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Ortonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Unnebrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Camez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the CHAMPION Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,11,28]]},"reference":[{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJM199502023320512","article-title":"Methotrexate for chronic diseases in adults","volume":"332","author":"Weinblatt","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis: consensus conference","volume":"38","author":"Roenigk","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1468-3083.2000.00058.x","article-title":"Methotrexate in psoriasis: 26\u2003years\u2019 experience with low-dose long-term treatment","volume":"14","author":"Haustein","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clindermatol.2003.08.015","article-title":"Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis","volume":"21","author":"Victor","year":"2003","journal-title":"Clin Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB6|cit6","first-page":"241","article-title":"Molecular differences in anticytokine therapies","volume":"21","author":"Calabrese","year":"2003","journal-title":"Clin Exp Rheumatol"},{"issue":"3, Part II","key":"10.1111\/j.1365-2133.2007.08315.x-BIB7|cit7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2003.10.008","article-title":"Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial","volume":"50","author":"Chen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in moderate to severe psoriasis patients: double-blind, randomized controlled trial and open-label extension study","volume":"4","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 3","key":"10.1111\/j.1365-2133.2007.08315.x-BIB9|cit9","first-page":"203","article-title":"Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis","volume":"52","author":"Langley","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","article-title":"An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis","volume":"139","author":"Lebwohl","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archderm.141.1.31","article-title":"Efficacy and safety observed during 24\u2003weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis","volume":"141","author":"Menter","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","article-title":"Efalizumab for patients with moderate to severe plaque psoriasis","volume":"290","author":"Gordon","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis: oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB17|cit17","unstructured":"Ko H-S Clinical trial design in psoriasis http:\/\/www.fda.gov\/OHRMS\/DOCKETS\/ac\/03\/briefing\/3933B1_01_Genentech-Raptiva.pdf"},{"issue":"Suppl. 69","key":"10.1111\/j.1365-2133.2007.08315.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2004.06070.x","article-title":"Biological therapies in the systemic management of psoriasis: International Consensus Conference","volume":"151","author":"Sterry","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1067\/mjd.2000.103983","article-title":"Clearance is not a realistic expectation of psoriasis treatment","volume":"42","author":"Al-Suwaidan","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB20|cit20","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","author":"Revicki","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB21|cit21","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.2006.066761","article-title":"Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial","volume":"66","author":"Burmester","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1365-2133.2006.07503.x","article-title":"Plasma homocysteine and folate levels in patients with chronic plaque psoriasis","volume":"155","author":"Malerba","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1161\/01.RES.0000087642.01082.E4","article-title":"Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes","volume":"93","author":"Zeng","year":"2003","journal-title":"Circ Res"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB26|cit26","first-page":"129","article-title":"Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis","volume":"138","author":"Nickoloff","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1111\/j.1365-2133.2007.08315.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/1523-1747.ep12363613","article-title":"MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions","volume":"101","author":"Gillitzer","year":"1993","journal-title":"J Invest Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2007.08315.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2007.08315.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:23:32Z","timestamp":1676366612000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/158\/3\/558\/6643818"}},"subtitle":["Adalimumab vs. methotrexate in psoriasis"],"short-title":[],"issued":{"date-parts":[[2007,11,28]]},"references-count":27,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08315.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1104566.560619","asserted-by":"object"}]},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,28]]}}}